Regarding new treatments, the thrombopoietin receptor agonist eltrombopag induced a sustained hemoglobin increase and > 50% reduction of transfusion requirements in one out of 15 adult patients with DBA. This evidence concerns the gene MPL and Diamond-Blackfan anemia.